Search Results for: MARKET BRIEF The Market for


July 9, 2014

BIOSIMILARS - The US Biosimilar Approval Pathway: Policy Precedes Science July 9, 2014

David Shoemaker, PhD, says the origin of the BPCIA had its roots in the Drug Price Competition and Patent Restoration Act of 1984 championed by Senators Waxman and Hatch, which has provided low-cost generic alternatives to prescription brand-name drugs for the three subsequent decades. What Congress failed to appreciate at the time was the current state of protein characterization science and consequently whether interchangeability could in fact be obtained or what level of biosimilarity was acceptable.

July 17, 2011

7/19/2011 July 17, 2011

Catalent & Sanwa Announce Exclusive License Agreement Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into...